| Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer. | |
| | |
MedLine Citation:
|
PMID: 22484576 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: The tolerance and safety associated with the administration order of the anthracycline and taxane drugs have not been evaluated. PATIENTS AND METHODS: Breast cancer patients with node-positive or high-risk patients with node-negative were eligible. The feasibility and toxicity were evaluated in the following regimens-arm A, 3 courses of fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) followed by 3 courses of docetaxel 100 mg/m(2) (DOC); arm B, 3 courses of DOC followed by 3 courses of FEC. RESULTS: Forty-two patients were registered. The relative dose intensity was 94.2 % for FEC and 97.8 % for DOC in arm A, and 98.9 % for DOC and 95.2 % for FEC in arm B. In arm A, grade 3 or higher hematological toxicity was observed in nine patients, and febrile neutropenia developed in three patients with FEC. In arm B, grade 3 or higher hematological toxicity was observed in seven patients, but febrile neutropenia was not noted in any patient. CONCLUSION: The regimens in both arms A and B were safe regarding adjuvant chemotherapy for early breast cancer. However, DOC followed by FEC might be more tolerable. Further studies will maximize the results obtained with DOC followed by FEC. |
| | |
Authors:
|
Hajime Abe; Tsuyoshi Mori; Yuki Kawai; Hirotomi Cho; Yoshihiro Kubota; Tomoko Umeda; Yoshimasa Kurumi; Tohru Tani |
Related Documents
:
|
22287756 - Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mcrpc): ... 16334136 - Biological prognostic factors in adult soft tissue sarcomas. 11734116 - Sarcomas of the head and neck. 22527186 - Risk factors for 6-month continuation of s-1 adjuvant chemotherapy for gastric cancer. 18566326 - The natural history and treatment outcome of blast phase bcr-abl- myeloproliferative ne... 15195896 - Hepatic transit time of an echo enhancer: an indicator of metastatic spread to the liver. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-4-7 |
Journal Detail:
|
Title: International journal of clinical oncology / Japan Society of Clinical Oncology Volume: - ISSN: 1437-7772 ISO Abbreviation: - Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-4-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9616295 Medline TA: Int J Clin Oncol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of Breast and General Surgery, Shiga University of Medical Science Hospital, Seta-Tsukinowa, Otsu, Shiga, 520-2192, Japan, abe@belle.shiga-med.ac.jp. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Acute inflammation with induction of anaphylatoxin C5a and terminal complement complex C5b-9 associa...
Next Document: Association of polymorphisms in non-classic MHC genes with susceptibility to autoimmune hepatitis.